CARCINOEMBRYONAL ANTIGEN IDIOTYPE VACCINE

癌胚抗原独特型疫苗

• 批准号: 3493386
• 负责人: HANS J HANSEN
• 金额: $ 5万
• 依托单位: IMMUNOMEDICS, INC.
• 依托单位国家: 美国
• 财政年份: 1993
• 资助国家: 美国
• 起止时间: 1993-05-25 至 1993-11-24
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3493386
• 关键词: active immunization; antiidiotype antibody; antitumor antibody; carcinoembryonal antigen; hamsters; immune tolerance /unresponsiveness; immunity; synthetic tumor antigen; technology /technique development

DESCRIPTION: (Adapted from the applicant's abstract) Cancer patients are usually tolerant to the antigens expressed on tumor cells. Triggering an active immune response by the patients to tumor-associated antigens represents one of the most promising prospects in cancer therapy. In this project, the investigators propose a preclinical study of the anti-idiotype approach to trigger an active immune response against CEA. Certain anti-idiotypic antibodies directed against the variable regions of antibodies specific for a given antigen can mimic (i.e., bear the internal image of) this antigen. In several experimental systems, immunization with anti-idiotypic antibodies elicited specific immunity in lieu of the original antigen. Immunization with anti- idiotype antibodies as surrogate antigens is a promising approach to trigger immunity to tolerized antigens such as tumor antigens. They have already generated baboon polyclonal and rat monoclonal anti-idiotype antibodies that antigenically mimic CEA. In this project they will assess whether these anti-idiotype antibodies can function as surrogate antigens in hamsters. Hamsters have been chosen since they are the only known non-immunodeficient animal species in which human CEA-producing tumors may grow. Hamsters represent a unique model to test whether active anti-idiotype immunization can protect against tumor growth. This Phase I study will represent the basis for more extensive preclinical and clinical studies in Phase II.

描述：（改编自申请人摘要）癌症患者 通常对肿瘤细胞上表达的抗原具有耐受性。 触发患者对肿瘤相关免疫反应的主动免疫应答 抗原代表了癌症治疗中最有前途的前景之一， 疗法 在这个项目中，研究人员提出了一项临床前研究， 抗独特型方法来引发主动免疫反应 反对CEA。 某些抗独特型抗体针对 对给定抗原特异的抗体的可变区可以模拟 (i.e.,带有）这个抗原的内部图像。 在几个实验 系统，用抗独特型抗体免疫引起特异性 免疫力来代替原始抗原 抗- 作为替代抗原的独特型抗体是一种有前途的方法， 触发对耐受化抗原如肿瘤抗原的免疫。 他们有 已生成狒狒多克隆和大鼠单克隆抗独特型 抗原模拟CEA的抗体。 在这个项目中，他们将 评估这些抗独特型抗体是否可以作为替代物 仓鼠体内的抗原 选择仓鼠是因为它们是唯一 已知的非免疫缺陷动物物种，其中产生人CEA的 肿瘤可能会生长。仓鼠代表了一种独特的模型来测试是否活跃 抗独特型免疫可以防止肿瘤生长。 这个阶段 我的研究将代表更广泛的临床前和 II期临床研究。